Trade

with

GTx Inc
(NASDAQ: GTXI)
AdChoices
0.6246
-0.0154
-2.41%
After Hours :
-
-
-

Open

0.6600

Previous Close

0.6400

Volume (Avg)

65.49k (207.20k)

Day's Range

0.6152-0.6804

52Wk Range

0.4100-2.35

Market Cap.

48.65M

Dividend Rate ( Yield )

-

Beta

1.22

Shares Outstanding

76.01M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • -

    • Net Income

    • -

    • Market Cap.

    • 48.65M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.22

    • Forward P/E

    • -1.73

    • Price/Sales

    • -

    • Price/Book Value

    • 3.11

    • Price/Cash flow

    • -1.13

      • EBITDA

      • -

      • Return on Capital %

      • -139.32

      • Return on Equity %

      • -183.10

      • Return on Assets %

      • -139.32

      • Book Value/Share

      • 0.20

      • Shares Outstanding

      • 76.01M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 2.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.34

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 4.98

              • 2.92

              • Quick Ratio

              • 4.66

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.25

              • 2.21

              • Book Value/Share

              • 0.20

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.13

                • 217.39

                • P/E Ratio 5-Year High

                • -20.04

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.75

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.52

                • Price/Book Value

                • 3.08

                • 8.61

                • Price/Cash Flow Ratio

                • -1.13

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -183.10

                        (-114.00)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -139.32

                        (-46.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -183.10

                        (-114.00)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • -

                      • 0.55

                      Current Historical
                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      GTx, Inc. is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathw...moreays to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients...more with advanced non-small cell lung cancer. The Company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company’s most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.lessless

                      Key People

                      Mr. Marc S. Hanover

                      COO/Founder/President/CEO

                      Mr. J.R. Hyde, III

                      Chairman of the Board/Director

                      Mr. Jason T. Shackelford

                      CFO/Controller/Other Corporate Officer/Chief Accounting Officer

                      Jeffrey G. Hesselberg

                      Vice President, Divisional

                      Henry P. Doggrell

                      General Counsel/Other Executive Officer/Secretary/Vice President

                      • GTx Inc

                      • 175 Toyota Plaza

                      • Memphis, TN 38103

                      • USA.Map

                      • Phone: +1 901 523-9700

                      • Fax: +1 901 844-8075

                      • gtxinc.com

                      Incorporated

                      1997

                      Employees

                      32